These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 33719370)

  • 1. Bempedoic Acid (Nexletol) for the Treatment of Hyperlipidemia and Familial Hypercholesterolemia.
    Lawrence E; Johns T
    Am Fam Physician; 2021 Mar; 103(6):377-378. PubMed ID: 33719370
    [No Abstract]   [Full Text] [Related]  

  • 2. Bempedoic Acid: A New Drug for an Old Problem.
    Nguyen D; Du N; Sulaica EM; Wanat MA
    Ann Pharmacother; 2021 Feb; 55(2):246-251. PubMed ID: 32674598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating pharmacokinetics of bempedoic acid in the treatment of hypercholesterolemia.
    Cicero AFG; Fogacci F; Cincione I
    Expert Opin Drug Metab Toxicol; 2021 Sep; 17(9):1031-1038. PubMed ID: 34197267
    [No Abstract]   [Full Text] [Related]  

  • 4. Bempedoic Acid: a cholesterol lowering agent with a novel mechanism of action.
    Nguyen H; Akamnonu I; Yang T
    Expert Rev Clin Pharmacol; 2021 May; 14(5):545-551. PubMed ID: 33691561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical development of bempedoic acid: phase 2 and phase 3 clinical trials.
    Lekuona I; Pintó X
    Clin Investig Arterioscler; 2021 May; 33 Suppl 1():58-64. PubMed ID: 33966815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bempedoic Acid: A New Tool in the Battle Against Hyperlipidemia.
    Powell J; Piszczatoski C
    Clin Ther; 2021 Feb; 43(2):410-420. PubMed ID: 33384162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance.
    Laufs U; Banach M; Mancini GBJ; Gaudet D; Bloedon LT; Sterling LR; Kelly S; Stroes ESG
    J Am Heart Assoc; 2019 Apr; 8(7):e011662. PubMed ID: 30922146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bempedoic acid, an inhibitor of ATP citrate lyase for the treatment of hypercholesterolemia: early indications and potential.
    Brandts J; Ray KK
    Expert Opin Investig Drugs; 2020 Aug; 29(8):763-770. PubMed ID: 32564642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bempedoic Acid for the Prevention of Cardiovascular Disease.
    Mounsey A; Jeyaraju M
    Am Fam Physician; 2024 Jun; 109(6):573-574. PubMed ID: 38905559
    [No Abstract]   [Full Text] [Related]  

  • 10. A Review of the Efficacy and Tolerability of Bempedoic Acid in the Treatment of Hypercholesterolemia.
    Niman S; Rana K; Reid J; Sheikh-Ali M; Lewis T; Choksi RR; Goldfaden RF
    Am J Cardiovasc Drugs; 2020 Dec; 20(6):535-548. PubMed ID: 32166726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bempedoic Acid for Heterozygous Familial Hypercholesterolemia: From Bench to Bedside.
    Agarwala A; Quispe R; Goldberg AC; Michos ED
    Drug Des Devel Ther; 2021; 15():1955-1963. PubMed ID: 34007155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bempedoic acid (Nexletol) for lowering LDL-cholesterol.
    Med Lett Drugs Ther; 2020 Apr; 62(1595):53-55. PubMed ID: 32324179
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial.
    Ballantyne CM; Davidson MH; Macdougall DE; Bays HE; Dicarlo LA; Rosenberg NL; Margulies J; Newton RS
    J Am Coll Cardiol; 2013 Sep; 62(13):1154-62. PubMed ID: 23770179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Greater than expected reduction in low-density lipoprotein-cholesterol (LDL-C) with bempedoic acid in a patient with heterozygous familial hypercholesterolemia (HeFH).
    Agha AM; Jones PH; Ballantyne CM; Virani SS; Nambi V
    J Clin Lipidol; 2021; 15(5):649-652. PubMed ID: 34393074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of bempedoic acid for prevention of cardiovascular events and diabetes: a systematic review and meta-analysis.
    Wang X; Zhang Y; Tan H; Wang P; Zha X; Chong W; Zhou L; Fang F
    Cardiovasc Diabetol; 2020 Aug; 19(1):128. PubMed ID: 32787939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bempedoic acid. Mechanism of action and pharmacokinetic and pharmacodynamic properties.
    Masana Marín L; Plana Gil N
    Clin Investig Arterioscler; 2021 May; 33 Suppl 1():53-57. PubMed ID: 33966814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bempedoic acid as adjunct for traditional lipid-lowering therapy in patients with hyperlipidaemia.
    Schimmenti C; Sucato V; Manzone E; Cancellieri G; Mortillaro F; Novo G; Galassi AR; Venturella F
    Coron Artery Dis; 2021 Jun; 32(4):340-344. PubMed ID: 33229935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New horizons in lipid management.
    Kane JP
    J Am Coll Cardiol; 2013 Sep; 62(13):1163-4. PubMed ID: 23770169
    [No Abstract]   [Full Text] [Related]  

  • 19. Bempedoic acid safety analysis: Pooled data from four phase 3 clinical trials.
    Bays HE; Banach M; Catapano AL; Duell PB; Gotto AM; Laufs U; Leiter LA; Mancini GBJ; Ray KK; Bloedon LT; Sasiela WJ; Ye Z; Ballantyne CM
    J Clin Lipidol; 2020; 14(5):649-659.e6. PubMed ID: 32980290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new indication for bempedoic acid (Nexletol).
    Med Lett Drugs Ther; 2024 May; 66(1702):75-77. PubMed ID: 38696311
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.